ag视讯真人彩票 黄金城游戏

As is disclosed recently by Liu Qian, the Director of Biotechnology Engineering Center under Chinese Ministry of Science and Technology, the following 5 years will witness China's transfer from current fund oriented support for biotech research and associated industrialization to policy oriented encouragement. Authorities concerned in this country are now working on a series of policies that will allow biotech industries to enjoy the same treatment as their software counterparts do. These favors include: no ownership restrictions will be imposed on the enterprises engaged in biotech research and industrialization; biotech industries will be favored with their IPO applications; the venture capital invested in biotech industries will enjoy income tax exemption; and the biotech products of independent intellectual property rights will also enjoy the tax holidays.

Liu also briefed that during the 10th Five-Year Plan period(2001-2005), the Nat ional 863 Program's budget dedicated to the biotech sector would be 4 to 5 times the combine d totals in the past 15 years, reaching RMB 5 billion. By then the overall capacity of China's biotech research and industrialization will be greatly accelerated to rank in the world advanced level in a decade.

To strengthen the innovation capacity of China's biotech industries, China will pay priority attention to the construction of 20 world class R&D bases and organize massive research activities in the fields of genome, bioinformation and biochips, tissues and organs engineering, animal-plant based biological reactor, genetic transfer modulation, genetic cell therapy, high flux screening and bioengineering and techniques.

Source from Chinagate